...
首页> 外文期刊>Tissue engineering, Part A >Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo ((polyethylene glycol) fumarate) hydrogels.
【24h】

Sustained delivery of dibutyryl cyclic adenosine monophosphate to the transected spinal cord via oligo ((polyethylene glycol) fumarate) hydrogels.

机译:经由低聚((聚乙二醇)富马酸酯)水凝胶将二丁酰基环状单磷酸腺苷持续输送至横断的脊髓。

获取原文
获取原文并翻译 | 示例
           

摘要

This study describes the use of oligo [(polyethylene glycol) fumarate] (OPF) hydrogel scaffolds as vehicles for sustained delivery of dibutyryl cyclic adenosine monophosphate (dbcAMP) to the transected spinal cord. dbcAMP was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres, which were embedded within the scaffolds architecture. Functionality of the released dbcAMP was assessed using neurite outgrowth assays in PC12 cells and by delivery to the transected spinal cord within OPF seven channel scaffolds, which had been loaded with Schwann cells or mesenchymal stem cells (MSCs). Our results showed that encapsulation of dbcAMP in microspheres lead to prolonged release and continued functionality in vitro. These microspheres were then successfully incorporated into OPF scaffolds and implanted in the transected thoracic spinal cord. Sustained delivery of dbcAMP inhibited axonal regeneration in the presence of Schwann cells but rescued MSC-induced inhibition of axonal regeneration. dbcAMP was also shown to reduce capillary formation in the presence of MSCs, which was coupled with significant functional improvements. Our findings demonstrate the feasibility of incorporating PLGA microsphere technology for spinal cord transection studies. It represents a novel sustained delivery mechanism within the transected spinal cord and provides a platform for potential delivery of other therapeutic agents.
机译:这项研究描述了寡聚[(聚乙二醇)富马酸酯](OPF)水凝胶支架作为媒介物,用于将二丁酰环状单磷酸腺苷(dbcAMP)持续递送至横切脊髓。 dbcAMP封装在聚乳酸-乙醇酸(PLGA)微球中,该微球嵌入支架结构中。使用PC12细胞中的神经突生长测定,并通过递送至OPF的七个通道支架中的横断脊髓,评估了释放的dbcAMP的功能,该支架已装有Schwann细胞或间充质干细胞(MSC)。我们的结果表明,dbcAMP在微球中的封装导致体外释放和持续功能。然后将这些微球成功地整合到OPF支架中,并植入到横切的胸脊髓中。 dbcAMP的持续传递在存在雪旺氏细胞的情况下抑制了轴突再生,但挽救了MSC诱导的轴突再生抑制作用。 dbcAMP还显示出在存在MSC的情况下减少了毛细血管的形成,并伴随着重大的功能改进。我们的发现证明了将PLGA微球技术纳入脊髓横断研究的可行性。它代表了横断脊髓内的新型持续递送机制,并为其他治疗药物的潜在递送提供了平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号